



## UNITED STATE EPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

TON NO.	FILING DATE	FIRST NAMED INVENTOR		TA	TORNEY DOCKET NO.
01,430	03/10/99	PARIKH		I	121-160
			¬ [	EXAMINER	
		HM12/0810			
NORTH AND VANDERING				<u>WARE T</u>	<del></del>
1100 NORTH GLEBE ROAD				ART UNIT	PAPER NUMBER
FLOOR					
NGTON V	/A 22201-47:	14		1615	11
				DATE MAILED:	11
					08/10/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

$\sim$	Application No.	Applicant(s)					
Advisory Action	09/281,430	PARIKH ET AL.					
Advisory Action	Examin r	Art Unit					
	Todd D Ware	1615					
Th MAILING DATE of this communication app ars on the cov r sh et with the correspondence address							
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.							
PERIOD FOR REPLY [check either a) or b)]							
a) The period for reply expires 3 months from the mailing date of b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later th ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	isory Action, or (2) the date set forth in th an SIX MONTHS from the mailing date o FILED WITHIN TWO MONTHS OF THI	f the final rejection. E FINAL REJECTION. See MPEP					
Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of extension CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moterned patent term adjustment. See 37 CFR 1.704(b).	sion and the corresponding amount of the I statutory period for reply originally set in	e fee. The appropriate extension fee under the final Office action; or (2) as set forth in					
1. ☐ A Notice of Appeal was filed on <u>27 July 2001</u> . App 37 CFR 1.192(a), or any extension thereof (37 CF							
$2. \boxtimes$ The proposed amendment(s) will not be entered b	ecause:						
(a) X they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) they raise the issue of new matter (see Note below);							
(c) ☐ they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mat	erially reducing or simplifying the					
(d) they present additional claims without cancel	ing a corresponding number of	finally rejected claims.					
NOTE: See Continuation Sheet.							
3. Applicant's reply has overcome the following rejection	tion(s):						
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a s	separate, timely filed amendment					
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly					
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims w							
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: <u>1-21</u> .							
Claim(s) withdrawn from consideration:							
B. ☐ The proposed drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.							
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)							
10. Other:							
		•					

Continuation of 2. NOTE: Finally rejected claims only required particle sizes of at most 10 microns, while the unentered amendments of 7-27-01 require particle sizes between 2 and 10 microns. Also, instant claims require an anti-cancer drug and do not specify anti-neoplastic or cytotoxic agents.

HURICAN PAGE SUPERVISORY PATENT EXAMINED TECHNOLOGY CENTER 1600